Health Economics›Marginal zone lymphoma›First-line therapy randomized data

First-line therapy randomized data

Marginal zone lymphoma · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib monotherapy Variant #01	—	R 80 133	28d	~44.1 mo	—	~48	~R 3 846 377 PFS proxy · indirect	15
R-CHOP Variant #23	—	R 59 865	21d	~44.4 mo	—	~65	~R 3 891 219 PFS proxy · indirect	4
Bendamustine and Rituximab (BR) Variant #12	—	R 40 807	28d	~39.6 mo	—	~44	~R 1 795 506 PFS proxy · indirect	18
R-CVP Variant #01	—	R 12 182	21d	—	—	—	—	1
Fludarabine monotherapy Variant #01	—	R 11 691	28d	—	—	—	—	1
Chlorambucil monotherapy Variant #12	—	R 2 523	14d	—	69.5 mo	—	—	1
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~20.3 mo	—	~4	~R 208 PFS proxy · indirect	17

7 of 7 regimens shown